Eficacia de la teleterapia en los adultos mayores del Centro del Adulto Mayor Santiago, Cusco, 2022

La presente investigación “Eficacia de la Teleterapia en los adultos mayores del centro del adulto mayor Santiago, Cusco, 2022” cuyo objetivo es demostrar la eficacia de la Teleterapia. La metodología fue de diseño cuasiexperimental, de método científico, de tipo aplicado, de alcance explicativo. La población estuvo conformada por 70 personas que cumplieron con los criterios de inclusión. Se diseño un instrumento que incluía el Senior Fitness Test, además del Índice de Barthel y la valoración de la adaptabilidad del uso de la plataforma ZOOM. Los resultados obtenidos fueron: en cuanto a la edad el mayor porcentaje 27,1% eran de adultos mayores de 70-74 años, además el 85,7% de la muestra eran mujeres. Para la dimensión acondicionamiento físico se tomó en cuenta los siguientes indicadores: indicador sentarse y levantarse de una silla (Chair stand test), los resultados luego del análisis arrojan que el 51,5% ha experimentado una mejoría. Indicador flexiones del brazo (Arm curl test) se halló que el 58,6% ha experimentado una mejoría. Indicador flexión del tronco en silla (Chair-sit and reach test) se halló que 64,2% de los participantes experimentaron una mejoría. Para la dimensión Actividades de la Vida Diaria arroja que un 10% alcanzo el nivel de independencia. Al análisis podemos afirmar que mediante el uso frecuente de los TIC’s los adultos mayores pueden adaptarse sin dificultad. En la prueba de hipótesis p = 0,000 el cual es menor al nivel de significancia esperado =0,05 . Por tanto, se concluye que la Teleterapia resulta significativamente eficaz al analizar los resultados obtenidos

Production of He-4 and (4) in Pb-Pb collisions at root(NN)-N-S=2.76 TeV at the LHC

Results on the production of He-4 and (4) nuclei in Pb-Pb collisions at root(NN)-N-S = 2.76 TeV in the rapidity range vertical bar y vertical bar <1, using the ALICE detector, are presented in this paper. The rapidity densities corresponding to 0-10% central events are found to be dN/dy4(He) = (0.8 +/- 0.4 (stat) +/- 0.3 (syst)) x 10(-6) and dN/dy4 = (1.1 +/- 0.4 (stat) +/- 0.2 (syst)) x 10(-6), respectively. This is in agreement with the statistical thermal model expectation assuming the same chemical freeze-out temperature (T-chem = 156 MeV) as for light hadrons. The measured ratio of (4)/He-4 is 1.4 +/- 0.8 (stat) +/- 0.5 (syst). (C) 2018 Published by Elsevier B.V.Peer reviewe

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Microeconomía - EN10 - 202101

Descripción: El curso de Microeconomía es de tipo general para estudiantes de Derecho que han aprobado el curso de Economía Política y que, por consiguiente, cuentan con los conocimientos básicos generales de la Economía. Se trata ahora de profundizar en las características de los mercados, en el concepto económico del lucro cesante a través de la compresión económica de los derechos de propiedad, del costo de oportunidad, en los conceptos de equilibrio y desequilibrio de los mercados, en la evaluación del comportamiento del Estado interventor e, igualmente, en la distinción necesaria entre el beneficio contable y el beneficio económico, con mayor exigencia de razonamiento y básico para la comprensión del peritaje especializado. Propósito: A través del estudio de la Microeconomía, los estudiantes de Derecho, encontrarán que se trata de una especialización en el estudio del fenómeno económico que busca encontrar relacione interdisciplinarias con el Derecho a fin de comprender la toma de decisiones de los individuos y como éstas influyen en su comportamiento social. Derecho y Economía son ciencias sociales que se complementan perfectamente y sirven de base para el análisis jurídico. Igualmente proporciona elementos válidos para el desempeño de un Abogado en el campo empresarial. El curso privilegia el desarrollo de la competencia general de razonamiento cuantitativo en un nivel 1, sin ser un curso de Economía pura, y que busca más bien encontrar la ligazón con el Derecho y las garantías constitucionales.

Por Antonio Melchor Fernandez de Hijar, Conde de Belchite ... Con Antonio Francisco Pimentèl, Conde Duque de Benavente ... y con Pasqual Enriquez de Cabrera, Marquès de Alcañizas ... Miguel Ignacio de Toledo Enriquez de Guzman, Conde de Villada ...Bartholome Enriquez Alvarez de Toledo, Marquès de Valparayso ... Joachin Enriquez de Oro, Marquès de Llaneras ... Fernando de Prado, Marques de Prado ... : sobre la succession en propriedad del Estado, y Condado de Alva de Aliste, y sus Agregados

Respétase a puntuación orixinalTexto asinado polo "Doct. Rodulfo Arredondo Carmona" que aparece noutros textos datados en 1714Precede a tít.: Jesus, Maria, Joseph con orla tipSign.: A-Z\p2\s, 2A-2B\p2\s, 2C\p1\

Multiplicity dependence of light (anti-)nuclei production in p–Pb collisions at sNN=5.02 TeV

The measurement of the deuteron and anti-deuteron production in the rapidity range −1 < y < 0 as a function of transverse momentum and event multiplicity in p–Pb collisions at √sNN = 5.02 TeV is presented. (Anti-)deuterons are identified via their specific energy loss dE/dx and via their time-of- flight. Their production in p–Pb collisions is compared to pp and Pb–Pb collisions and is discussed within the context of thermal and coalescence models. The ratio of integrated yields of deuterons to protons (d/p) shows a significant increase as a function of the charged-particle multiplicity of the event starting from values similar to those observed in pp collisions at low multiplicities and approaching those observed in Pb–Pb collisions at high multiplicities. The mean transverse particle momenta are extracted from the deuteron spectra and the values are similar to those obtained for p and particles. Thus, deuteron spectra do not follow mass ordering. This behaviour is in contrast to the trend observed for non-composite particles in p–Pb collisions. In addition, the production of the rare 3He and 3He nuclei has been studied. The spectrum corresponding to all non-single diffractive p-Pb collisions is obtained in the rapidity window −1 < y < 0 and the pT-integrated yield dN/dy is extracted. It is found that the yields of protons, deuterons, and 3He, normalised by the spin degeneracy factor, follow an exponential decrease with mass number

Alirocumab and cardiovascular outcomes after acute coronary syndrome

BACKGROUN